Blockchain Registration Transaction Record

NRx Pharmaceuticals Receives $4.3M FDA Waiver for NRX-100 Ketamine Therapy

NRx Pharmaceuticals announced a $4.3M FDA waiver for its NRX-100 ketamine therapy, signaling progress in treating suicidal depression. This development underscores the company's dedication to mental health innovation.

NRx Pharmaceuticals Receives $4.3M FDA Waiver for NRX-100 Ketamine Therapy

This news matters as it highlights NRx Pharmaceuticals' progress in developing a potentially groundbreaking therapy for suicidal depression. The FDA waiver signifies a significant step towards providing innovative treatment options for patients in need, showcasing the company's commitment to addressing mental health challenges.

BlockchainDetails
Contract Address0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71
Transaction ID0x580a43c9d6769eee8f0cc5c1b6d170d6f76fb0f1cfad23ae34e29ff863eb539d
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintbarnJgTh-280a5562546e0d1f59a51dafb8746040